Crown Equity Holdings Inc. (CRWE)
Watching online videos is now a mainstream activity. Video is way better at moving viewers to laugh, cry, get mad, learn and take action than photos, text or audio.
78% of people watch at least once a week and 55% watch everyday. YouTube alone has over 4 billion views per day, and it’s the second largest search engine next Google (which owns YouTube)
80% of Internet users recall watching a video ad on a website they visited in the past 30 days; 46% took some action after viewing the ad (Online Publishers Association)
BIA/Kelsey has projected that social media advertising spending will hit close to $10 billion by year 2016 well up from $4.8 billion spent in 2012.
According to Break Media, video ad spending will reach $5.4 Billion by 2016.
CRWE is targeting that multi-billion dollar video sharing industry with its Division CRWETube (www.crwetube.com)
Together with its digital network of Websites, CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.
CRWE focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. CRWE‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com.
Shares of Anacor Pharmaceuticals, Inc. (Nasdaq:ANAC) surged on Friday after the company reported that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc., successor in interest to Dow Pharmaceutical Sciences, Inc., has issued an Interim Final Award in favor of ANAC, awarding ANAC $100 million in damages as well as all costs of the arbitration and reasonable attorney’s fees.
On October 24, 2012, ANAC provided notice to Valeant seeking to commence arbitration with JAMS of a breach of contract dispute under a master services agreement dated March 26, 2004 between ANAC and Dow Pharmaceutical Sciences. This agreement related to certain development services provided by Dow Pharmaceutical Sciences in connection with ANAC’s efforts to develop its topical antifungal product candidate for the treatment of onychomycosis.
ANAC’s assertions included breach of contract, breach of implied covenant of good faith and fair dealing, misappropriation of trade secrets and unfair competition.
In addition to the claims related to this ruling, ANAC believes it has additional claims against Valeant related to separate contractual rights and intellectual property rights and is evaluating options for pursuing those claims independently of this decision.
ANAC last trade was $13.83, representing an increase of 28.41% or $3.06, with 2,706,878 shares traded on Friday.
ANAC is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.
More about Anacor Pharmaceuticals, Inc. (Nasdaq:ANAC) at www.anacor.com.
Read Full Disclaimer at www.mikezaman.com/disclaimer